Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

Clinical Trial Success:
Viridian Therapeutics announced positive topline data from its Phase 3 THRIVE-2 clinical trial evaluating veligrotug in patients with chronic thyroid eye disease (TED)25.

Efficacy Results:

Proptosis Response:
70% of patients receiving veligrotug achieved a proptosis response, compared to 5% in the placebo group2.

Diplopia Resolution:
54% of veligrotug-treated patients achieved complete diplopia resolution, compared to 12% in the placebo group2.

Rapid Onset:
53% of veligrotug-treated patients achieved a proptosis response after just one infusion2.

Safety Profile:
Veligrotug was generally well-tolerated, with most adverse events being mild and no treatment-related serious adverse events reported2.

Future Plans:
Viridian plans to submit a Biologics License Application for veligrotug in the second half of 20252.

Ongoing Trials:
The THRIVE-2 trial for chronic TED is ongoing, with top-line data expected by the end of 202425.

Sources:

2. https://www.optometrytimes.com/view/viridian-announces-positive-topline-data-from-phase-3-thrive-trial-assessing-veligrotug-in-patients-with-active-ted

5. https://investors.viridiantherapeutics.com/news/news-details/2024/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Veligrotug-Phase-3-THRIVE-2-Clinical-Trial-in-Patients-with-Chronic-Thyroid-Eye-Disease/default.aspx